Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.70 |
| ▸ | RAB9A | P51151 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3080186 | 1.00 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2GAAMEN1 | |
| SCHEMBL10798007 | 1.00 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2GAAMEN1 | |
| SCHEMBL5958238 | 0.87 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2GAAMEN1 | |
| SCHEMBL5958239 | 0.87 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2GAAMEN1 | |
| SCHEMBL5747589 | 0.87 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2GAAMEN1 | |
| SCHEMBL5746903 | 0.87 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2GAAMEN1 | |
| SCHEMBL8109792 | 0.86 | SMN1; SMN2 (0.64) | NPC1RAB9ASMN1; SMN2GAAMEN1 | |
| SCHEMBL8109795 | 0.86 | SMN1; SMN2 (0.64) | NPC1RAB9ASMN1; SMN2GAAMEN1 | |
| SCHEMBL28114466 | 0.86 | KMT2A (0.60) | NPC1RAB9ASMN1; SMN2GAAMEN1 | |
| SCHEMBL8625841 | 0.83 | GAA (0.88) | NPC1RAB9ASMN1; SMN2GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3227018-B1 | CHELATION DIRECTED C-H ACTIVATION REACTIONS CATALYZED BY SOLID-SUPPORTED PALLADIUM(II) CATALYSTS | UNIV VIRGINIA COMMONWEALTH (US) | 2021-06-30 | — | — | EP | disclosed |
| US-10000453-B2 | Chelation directed C—H activation reactions catalyzed by solid-supported palladium(II) catalysts | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170362181-A1 | CHELATION DIRECTED C-H ACTIVATION REACTIONS CATALYZED BY SOLID-SUPPORTED PALLADIUM(II) CATALYSTS | VIRGINIA COMMONWEALTH UNIVERSITY | 2017-12-21 | — | — | US | disclosed |
| CN-102471366-B | 17-hydroxy-17-pentafluoroethylestra-4, 9(10) -diene 11-benzylidene derivatives, process for preparing them and their use for treating diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-16 | — | — | CN | disclosed |
| CN-103102284-A | Preparation of 4-trifluoromethyl-2, 6-dinitrobenzene salicylaldoxime derivative and its application in anticancer therapeutic drugs | NANJING UNIVERSITY OF TECHNOLOGY | 2013-05-15 | — | — | CN | disclosed |
| US-20130004979-A1 | GLYCOSYLTRANSFERASE REVERSIBILITY FOR SUGAR NUCLEOTIDE SYNTHESIS AND MICROSCALE SCANNING | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130004979-A1 | GLYCOSYLTRANSFERASE REVERSIBILITY FOR SUGAR NUCLEOTIDE SYNTHESIS AND MICROSCALE SCANNING | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130004979-A1 | GLYCOSYLTRANSFERASE REVERSIBILITY FOR SUGAR NUCLEOTIDE SYNTHESIS AND MICROSCALE SCANNING | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-01-03 | — | — | US | disclosed |
| US-20100226875-A1 | CONTROLLED RELEASE OF ACTIVE COMPOUNDS FROM DYNAMIC MIXTURES | FIRMENICH SA (CH) | 2010-09-09 | — | — | US | disclosed |
| EP-2010293-A2 | CONTROLLED RELEASE OF ACTIVE COMPOUNDS FROM DYNAMIC MIXTURES | Firmenich S.A. (CH) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007085991-A2 | CONTROLLED RELEASE OF ACTIVE COMPOUNDS FROM DYNAMIC MIXTURES | FIRMENICH SA (CH) | 2007-08-02 | — | — | WO | disclosed |
| EP-1680421-A2 | USE OF TRICYCLIC COMPOUNDS AS GLYCINE TRANSPORT INHIBITORS | Sanofi-Aventis (FR) | 2006-07-19 | — | — | EP | disclosed |
| EP-1680400-A2 | DERIVATIVES OF N-[ PHENYL(PYRROLIDINE-2-YL)METHYL]BENZAMIDE AND N-[ (AZEPAN-2-YL)PHENYLMETHYL]BENZAMIDE, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005037785-A2 | DERIVATIVES OF N-[PHENYL(PYRROLIDINE-2-YL)METHYL]BENZAMIDE AND N-[(AZEPAN-2-YL)PHENYLMETHYL]BENZAMIDE, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037783-A2 | USE OF TRICYCLIC COMPOUNDS AS GLYCINE TRANSPORT INHIBITORS | SANOFI-AVENTIS (FR) | 2005-04-28 | — | — | WO | disclosed |
| US-6313290-B1 | Azolobenzazepine derivatives and compositions and method of use thereof | ZENECA LIMITED (GB) | 2001-11-06 | — | — | US | disclosed |
| US-6124281-A | TREATING STROKES | ZENECA LIMITED (GB) | 2000-09-26 | — | — | US | disclosed |
| EP-0888350-A1 | AZOLOBENZAZEPINE DERIVATIVES AS NEUROLOGICALLY ACTIVE AGENTS | ZENECA LIMITED (GB) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997032883-A1 | AZOLOBENZAZEPINE DERIVATIVES AS NEUROLOGICALLY ACTIVE AGENTS | ZENECA LIMITED (GB) | 1997-09-12 | — | — | WO | disclosed |
| US-4696964-A | HEAT RESISTANCE, OXIDATION RESISTANCE | CIBA-GEIGY CORPORATION (US) | 1987-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226875-A1 | CONTROLLED RELEASE OF ACTIVE COMPOUNDS FROM DYNAMIC MIXTURES | HPD, TRHDE, BPHL | NPC1 3753/4885RAB9A 3285/4885SMN1; SMN2 3885/4885 |
| US-20170362181-A1 | CHELATION DIRECTED C-H ACTIVATION REACTIONS CATALYZED BY SOLID-SUPPORTED PALLADIUM(II) CATALYSTS | WASF2, SCO2, SOD1 | NPC1 4103/4885RAB9A 1833/4885SMN1; SMN2 2900/4885 |
| US-10000453-B2 | Chelation directed C—H activation reactions catalyzed by solid-supported palladium(II) catalysts | WASF2, SOD1, CD274 | NPC1 4134/4885RAB9A 1800/4885SMN1; SMN2 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.